相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Olanzapine/Fluiloxietine A Review of its Use in Patients With Treatment-Resistant Major Depressive Disorder
Jamie D. Croxtall et al.
CNS DRUGS (2010)
Do atypical features affect outcome in depressed outpatients treated with citalopram?
Jonathan W. Stewart et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2010)
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder
D. W. Boulton et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2010)
Quetiapine XR: Current status for the treatment of major depressive disorder
Chi-Un Pae et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2010)
An Integrated Analysis of the Efficacy of Desvenlafaxine Compared with Placebo in Patients with Major Depressive Disorder
Michael E. Thase et al.
CNS SPECTRUMS (2009)
Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants
Robert M. Berman et al.
CNS SPECTRUMS (2009)
A review of the safety and tolerability of aripiprazole
Chi-Un Pae
EXPERT OPINION ON DRUG SAFETY (2009)
A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder
Frank C. Schieber et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2009)
Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning
Madhukar H. Trivedi et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2009)
Efficacy, safety and tolerability of quetiapine augmentation in treatment resistant depression: An open-label, pilot study
I. M. Anderson et al.
JOURNAL OF AFFECTIVE DISORDERS (2009)
Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression
Verena Henkel et al.
JOURNAL OF AFFECTIVE DISORDERS (2009)
Extended-Release Quetiapine as Adjunct to an Antidepressant in Patients With Major Depressive Disorder: Results of a Randomized, Placebo-Controlled, Double-Blind Study
Michael Bauer et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
Extended Release Quetiapine Fumarate Monotherapy in Major Depressive Disorder: A Placebo- and Duloxetine-Controlled Study
Andrew J. Cutler et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
Depression-like deficits in rats improved by subchronic modafinil
Ralf Regenthal et al.
PSYCHOPHARMACOLOGY (2009)
Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice
Michel Bourin et al.
PSYCHOPHARMACOLOGY (2009)
Difference in treatment outcome in outpatients with anxious versus nonanxious depression: A STAR*D report
Maurizio Fava et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: A preliminary trial
Yves Chaput et al.
BMC PSYCHIATRY (2008)
Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients
Jung-Ryul Kim et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Aripiprazole in the treatment of depressive and anxiety disorders: A review of current evidence
Chi-Un Pae et al.
CNS DRUGS (2008)
Metabolism of atypical antipsychotics: Involvement of cytochrome P450 enzymes and relevance for drug-drug interactions
Liana Urichuk et al.
CURRENT DRUG METABOLISM (2008)
Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug
Jonathan N. Bauman et al.
DRUG METABOLISM AND DISPOSITION (2008)
A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder
Amir Garakani et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2008)
Adjunctive Aripiprazole in Major Depressive Disorder: Analysis of Efficacy and Safety in Patients With Anxious and Atypical Features
Madhukar H. Trivedi et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
Anti psychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia - A systematic review
Keming Gao et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2008)
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder - A second multicenter, randomized, double-blind, placebo-controlled study
Ronald N. Marcus et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2008)
Potentiation of the Antidepressant-Like Effect of Fluoxetine by Aripiprazole in the Mouse Tail Suspension Test
Junzo Kamei et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2008)
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines
I. M. Anderson et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2008)
Aripiprazole as an adjunctive treatment for refractory unipolar depression
David J. Hellerstein et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2008)
Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants
Richard Hansen et al.
PSYCHIATRIC SERVICES (2008)
Triple Reuptake Inhibitors: A Premise and Promise
David M. Marks et al.
PSYCHIATRY INVESTIGATION (2008)
Outcomes in major depressive disorder: The evolving concept of remission and its implications for treatment
Hans-Juergen Moeller
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2008)
Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: A pooled survival analysis of 7 double-blind, randomized clinical trials
George I. Papakostas et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness - A double-blind, placebo-controlled study
Boadie W. Dunlop et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2007)
Differences in agonist/antagonist properties at human dopamine D2 receptors between aripiprazole, bifeprunox and SDZ 208-912
Yoshihiro Tadori et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression
Bret Rutherford et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2007)
Involvement of dopamine (DA)/serotonin (5-HT)/sigma (σ) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 doparnine receptor agonist
Ashish Dhir et al.
BRAIN RESEARCH BULLETIN (2007)
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study
Robert M. Berman et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: A meta-analysis
George I. Papakostas et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain
A. Bortolozzi et al.
PSYCHOPHARMACOLOGY (2007)
Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder
George I. Papakostas et al.
PSYCHIATRY RESEARCH (2007)
Treating depression with atypical features
Jonathan W. Stewart
JOURNAL OF CLINICAL PSYCHIATRY (2007)
Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: A 4-week open-label parallel-group study
Cornelius Schuele et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2007)
Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: Influence of CYP2D6 polymorphism
Masanori Kubo et al.
DRUG METABOLISM AND PHARMACOKINETICS (2007)
Aripiprazole augmentation for treatment of patients with inadequate antidepressants response
Chi-Un Pae et al.
DEPRESSION AND ANXIETY (2007)
Metabolic drug interactions with newer antipsychotics: A comparative review
Edoardo Spina et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2007)
Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients
Espen Molden et al.
THERAPEUTIC DRUG MONITORING (2006)
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report
A. John Rush et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
Open-label study of adjunct modafinil for the treatment of patients with fatigue, sleepiness, and major depression treated with selective serotonin reuptake inhibitors
Numan Konuk et al.
ADVANCES IN THERAPY (2006)
Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: A 12-week, open-label, extension study
ME Thase et al.
CNS SPECTRUMS (2006)
Methylphenidate-enhanced antidepressant response to citalopram in the elderly: A double-blind, placebo-controlled pilot trial
H Lavretsky et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2006)
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice
MH Trivedi et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: A meta-analysis of randomized clinical trials
PMJ Vis et al.
ANNALS OF PHARMACOTHERAPY (2005)
Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex
A Zocchi et al.
NEUROSCIENCE LETTERS (2005)
Antidepressant-like effects of selegiline in the forced swim test
S Shimazu et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2005)
Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder
JS Simon et al.
JOURNAL OF CLINICAL PSYCHIATRY (2005)
Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder
GI Papakostas et al.
JOURNAL OF CLINICAL PSYCHIATRY (2005)
Modafinil augmentation in depressed patients with partial response to antidepressants:: A pilot study on self-reported symptoms covered by the Major Depression Inventory (MDI) and the Symptom Checklist (SCL-92)
NA Rasmussen et al.
NORDIC JOURNAL OF PSYCHIATRY (2005)
Dopaminergic mechanism of antidepressant action in depressed patients
P Willner et al.
JOURNAL OF AFFECTIVE DISORDERS (2005)
Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors
DE Adson et al.
JOURNAL OF AFFECTIVE DISORDERS (2005)
Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients
JJ Worthington et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2005)
A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness
M Fava et al.
JOURNAL OF CLINICAL PSYCHIATRY (2005)
Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability
A DeLeon et al.
CLINICAL THERAPEUTICS (2004)
Atypical antipsychotics: Pharmacokinetics, therapeutic drug monitoring and pharmacological interactions
MA Raggi et al.
CURRENT MEDICINAL CHEMISTRY (2004)
Psychosocial functioning during the treatment of major depressive disorder with fluoxetine
GT Papakostas et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2004)
Enduring behavioral effects of early exposure to methylphenidate in rats
WA Carlezon et al.
BIOLOGICAL PSYCHIATRY (2003)
Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: A placebo-controlled 26-week study
TA Pigott et al.
JOURNAL OF CLINICAL PSYCHIATRY (2003)
Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: A preliminary double-blind, placebo-controlled study
C DeBattista et al.
JOURNAL OF CLINICAL PSYCHIATRY (2003)
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder
SG Potkin et al.
ARCHIVES OF GENERAL PSYCHIATRY (2003)
The epidemiology of major depressive disorder - Results from the National Comorbidity Survey Replication (NCS-R).
RC Kessler et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.
SR Marder et al.
SCHIZOPHRENIA RESEARCH (2003)
Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study
M Fava et al.
PSYCHIATRIC CLINICS OF NORTH AMERICA (2003)
Aripiprazole: A new atypical antipsychotic drug
TM Bowles et al.
ANNALS OF PHARMACOTHERAPY (2003)
Is there a role for 5-HT1A agonists in the treatment of depression?
P Blier et al.
BIOLOGICAL PSYCHIATRY (2003)
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder
JM Kane et al.
JOURNAL OF CLINICAL PSYCHIATRY (2002)
Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors
KD Burris et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Is dopamine implicated in the antidepressant-like effects of selective serotonin reuptake inhibitors in the mouse forced swimming test?
CE Renard et al.
PSYCHOPHARMACOLOGY (2001)
Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors:: Results from a placebo-controlled, randomized, double-blind, placebo wash-in study
BG Appelberg et al.
JOURNAL OF CLINICAL PSYCHIATRY (2001)
Effects of fluvoxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients:: a pet study
RM Moresco et al.
NEUROIMAGE (2000)
Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: A survey of current next-step practices
SJ Fredman et al.
JOURNAL OF CLINICAL PSYCHIATRY (2000)
Timing of onset of antidepressant response with fluoxetine treatment
AA Nierenberg et al.
AMERICAN JOURNAL OF PSYCHIATRY (2000)
分享论文
